How the Developments in Dry Eye Syndrome Treatment Have Benefited Individuals with Greater Efficacy

Who thinks tears are also a vital element in overall well-being? However, they are essential for maintaining the health and comfort of the eyes. Tears give adequate nourishment, moisture, and protection to the ocular surface. Dry eye syndrome is a complex eye condition in which the eyes are unable to produce enough tears and when the tears evaporate too quickly.  Though it is common for people aged 50 or above, in some cases individuals who are pregnant, undergoing any hormone replacement therapy, or experiencing menopause also have a greater risk of dry eye syndrome. This article talks about the crucial factors shaping the dry eye syndrome market such as new product launches and mergers and acquisitions among leading companies in the industry. 

Latest treatments for dry eye syndrome:

Usually, there are two main types of dry eye syndrome, one is known as aqueous deficient dry eye, in which individuals are unable to make sufficient tears to keep the surface lubricant. Another type is called evaporative dry eye, in which people can make tears but they vanish too quickly. Both types have multiple causes such as hormonal changes, the aging process, side effects of specific medications, and due to certain conditions, such as Sjögren's syndrome. 

The first line of treatment for dry eye syndrome is artificial tears, commonly referred to as OTC (over-the-counter) lubricating eye drops that can manage dry eye symptoms. In May 2023, the FDA approved Miebo (perfluorohexyloctane ophthalmic solution), a prescribed eye drop that is designed to treat tear evaporation effectively. In addition, many healthcare professionals prefer IPL (intense pulse light) therapy which can reduce inflammation, enhance blood flow around the eyes, and encourage proper function of the meibomian glands which are crucial for producing the oily layer of tears. These beneficial treatment options for dry eye syndrome can bring huge investment opportunities for the dry eye syndrome market. 

The global dry eye syndrome market is witnessing promising growth owing to the rising geriatric population and increasing screen time among individuals. Based on drugs, the dry eye syndrome drugs segment is expected to hold the largest market share in terms of revenue, by generating $2836.4 million over the analysis timeframe 2023-2032. Based on country, India is predicted to rise at a noteworthy CAGR of 10.4% from 2023 to 2032. On the contrary, Australia is expected to gain the second position, growing at a CAGR of 9.9% during the estimated period. 

Product launches:

To cater to the growing demand for novel ophthalmology treatments, many leading market players have come up with inventive product launches. A notable example is the launch of CEQUA, the first dry-eye treatment in India, by Sun Pharmaceutical Industries Limited, a leading Indian multinational pharmaceutical company. This product is developed with nano micellar (NCELL) technology and would be highly beneficial for patients having dry eye disease with inflammation. 

Another instance is the launch of VEVYE™ (cyclosporine ophthalmic solution) by Novaliq GmbH, a renowned biopharmaceutical company that has received approval from the FDA for treating chronic signs and symptoms of dry eye disease. VEVYE is the first cyclosporine solution that can treat dye eye syndrome with optimum safety and efficacy within four weeks. 

To wrap up, the global dry eye syndrome market is observing significant growth due to the increasing pervasiveness of critical eye diseases among individuals. Moreover, the continuous development of dry eye treatment options by top pharmaceutical companies may drive the market’s growth with immense opportunities. 

Related Post